Sotatercept (PAH Treatment)
Pulmonary Arterial Hypertension
Sponsor Merck (MSD)
600 Enrollment Target
110 Trial Sites
5 Countries
September 2027 Est. Completion
About This Trial
First-in-class activin signaling inhibitor as monotherapy for treatment-naive PAH.
Primary Endpoints
- 6-minute walk distance
- Time to clinical worsening
Latest Update
February 2026
FDA approved Winrevair (sotatercept) March 2024. HYPERION study exploring expanded use ongoing.